Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Konstantinos Leventakos
ResearcherPublications, citations & collaboration network
Konstantinos Leventakos is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 280 works, 4,121 citations, an h-index of 27 and an i10-index of 56.
280
Works
4,121
Citations
27
h-index
56
i10-index
How has Konstantinos Leventakos's publication output changed over time?
ScholarIQpublication output · 2009–2024
Output grew0% over the shown period — from 1 works in 2009 to 1 in 2024.
1
1
1
1
1
2
1
2
1
200920102011201320172019202220232024
What are the most-cited papers on Konstantinos Leventakos?
ScholarIQmost cited works
Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation
Pasi A. Jänne, Gregory J. Riely, Shirish M. Gadgeel, Rebecca S. Heist, Sai‐Hong Ignatius Ou, Jose M. Pacheco, Melissa L. Johnson, Joshua K. Sabari, Konstantinos Leventakos, Edwin Yau, Lyudmila Bazhenova, Marcelo V. Negrão, Nathan A. Pennell, Jun Zhang, Kenna Anderes, Hirak Der‐Torossian, Thian Kheoh, Karen Velastegui, Xiaohong Yan, James G. Christensen, Richard C. Chao, Alexander I. Spira
New England Journal of Medicine. 20221,015 CitationsOPEN ACCESS
Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
Narjust Duma, Jesus Vera Aguilera, Jonas Paludo, Candace L. Haddox, Miguel González Vélez, Yucai Wang, Konstantinos Leventakos, Joleen M. Hubbard, Aaron S. Mansfield, Ronald S. Go, Alex A. Adjei
Journal of Oncology Practice. 2017450 Citations
Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20‐year autopsy study
Russell E. Lewis, Lizebeth Cahyame‐Zuniga, Konstantinos Leventakos, Georgios Chamilos, Ronen Ben‐Ami, Pheroze Tamboli, Jeffrey J. Tarrand, Gerald P. Bodey, Mario A. Luna, Dimitrios P. Kontoyiannis
S80731565. 2013246 Citations
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer
Lars D. Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, David Trinh, Allan Hebbert, Christopher R. Smith, Svitlana Kulyk, J. David Lawson, Leo He, Laura D. Hover, Julio Fernandez-Banet, Jill Hallin, Darin Vanderpool, David M. Briere, Alice Blaj, Matthew A. Marx, Jordi Rodón, Michael Offin, Kathryn C. Arbour, Melissa L. Johnson, David J. Kwiatkowski, Pasi A. Jänne, Candace L. Haddox, Kyriakos P. Papadopoulos, Jason T. Henry, Konstantinos Leventakos, James G. Christensen, Ronald Shazer, Peter Olson
Cancer Discovery. 2023204 CitationsOPEN ACCESS
Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance
Ronen Ben‐Ami, Guillermo García‐Effrón, Russell E. Lewis, Soledad Gamarra, Konstantinos Leventakos, David S. Perlin, Dimitrios P. Kontoyiannis
S54542293. 2011166 CitationsOPEN ACCESS
Related on ScholarIQ
Mayo Clinic
Institution
Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation
Paper
Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
Paper
Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20‐year autopsy study
Paper
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer
Paper
Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance
Paper